Halia Therapeutics, Inc.

Halia Therapeutics, Inc. is a privately held, clinical-stage biopharmaceutical company headquartered in Lehi, Utah. Founded in 2017, the company is dedicated to advancing therapies that leverage insights from human biology and genetic resilience to address inflammatory disorders and neurodegenerative diseases. Its core mission is to decode natural protective mechanisms and translate them into treatments that improve and extend patients' lives.

Halia Therapeutics focuses on developing novel small-molecule therapies that target the immune system's inflammatory response, particularly through allosteric NEK7/NLRP3 inflammasome inhibition and LRRK2 inhibition. The company's pipeline includes lead clinical candidate ofirnoflast (HT-6184), an oral NEK7/NLRP3 inflammasome modulator, which is being developed for myelodysplastic syndromes (MDS) and metabolic diseases. Another key candidate, HT-4253, is an LRRK2 inhibitor aimed at neuroinflammation and Alzheimer's prevention. Halia utilizes its proprietary AI-powered GENMOR-AI platform to identify protective genetic modifiers and accelerate drug discovery across various therapeutic areas, including neurology, metabolism, immunology, and oncology.

Led by CEO Dr. David J. Bearss, Halia Therapeutics has achieved several notable milestones. In June 2026, its lead program, ofirnoflast (HT-6184), received FDA Fast Track Designation for lower-risk Myelodysplastic Syndromes, following positive Phase 2a data presented at ASH 2025. The company also received Orphan Drug Designation for ofirnoflast in MDS in October 2025. Halia completed a first-in-human Phase 1 study for HT-4253 in June 2025 and presented related data at AAIC 2026. The company continues to advance its clinical programs and is scheduled to present at the Morgan Stanley 24th Annual Global Healthcare Conference in September 2026.